 LEXINGTON, Mass., Oct. 04, 2021 GLOBE NEWSWIRE -- Keros Therapeutics, Inc. Keros Nasdaq: KROS, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced that it presented results from a preclinical study of KER-012 at the American Society for Bone and Mineral Research ASBMR 2021 Annual Meeting held October 1 through 4, 2021. 